Are all angiotensin-converting enzyme inhibitors interchangeable?

Area of Science:

• Pharmacology
• Clinical Medicine
• Drug Efficacy

Background:

• The proliferation of
• me-too
• drugs within popular classes raises questions about interchangeability.
• The concept of
• class effect
• lacks a universally accepted definition.
• While drugs within a class share primary actions, they may differ significantly in efficacy and safety.

Purpose of the Study:

• To review the concept of drug class effect.
• To examine the interchangeability of angiotensin-converting enzyme (ACE) inhibitors.
• To highlight the importance of evidence-based prescribing.

Main Methods:

• Literature review focusing on drug class effects.
• Analysis of clinical trial data for ACE inhibitors.
• Comparison of efficacy and safety profiles of available ACE inhibitors.

Main Results:

• Only 50% of the 10 ACE inhibitors available in the U.S. have demonstrated improved survival and reduced morbidity in heart failure or myocardial infarction.
• The safety and efficacy profiles, as well as optimal dosages, remain unknown for the other five ACE inhibitors.
• Significant clinical differences may exist between drugs within the same class, challenging the notion of interchangeability.

Conclusions:

• The interchangeability of all ACE inhibitors is not established.
• Prescribing practices should be guided by robust scientific evidence, not assumptions.
• Patients requiring ACE inhibitor therapy should receive agents with proven efficacy and safety profiles.